Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 Phase 3 in Moderate-to-Severe Atopic Dermatitis
CTR20220326Phase 3Completed
- Sponsor
- Keymed Biosciences
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing CM310 with Placebo (2 arms). Primary endpoints: EASI-75 response at Week 16 and IGA 0/1 with ≥2-point improvement at Week 16. Started Feb 2022; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20220326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220326.